BVMF/N1BI34 (BVMF/N1BI34)

Brazil Stock Exchange: BVMF/N1BI34 · BRL

R$39.0

-0.16 (-0.4%)· Recorded snapshot

Market cap	79.5B
Revenue (ttm)	17.5B
Net income (ttm)	3.7B
EPS (ttm)	R$1.83
P/E (trailing)	21.3x
P/E (forward)	12.1x
Volume	65
Beta	0.40

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 17.5B
Net income (ttm): 3.7B
EPS (ttm): R$1.83
P/E (trailing): 21.3x
P/E (forward): 12.1x
Market cap: 79.5B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/E12.1

P25 n/aP50 n/aP75 n/a

Trailing P/E21.3

P25 n/aP50 n/aP75 n/a

ROE22.1

P25 n/aP50 n/aP75 n/a

ROIC20.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BVMF/N1BI34 indicators

Market & fundamental data

Available fields

235

Groups with data

Currency

USD

Showing 235 of 235 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	BRL
Country	United States
Country code	BR
Earnings date	2026-11-02
Employees	2,500
Employees change	400
Employees growth	28.57%
Enterprise value	BRL 79.9B
Exchange	Brazil Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1992
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	No
ISIN number	BRN1BIBDR009
Last earnings date	2026-07-30
Last refreshed	2026-10-29
Market cap	BRL 79.5B
Next earnings date	2026-11-02
Price	BRL 39.04
Price currency	BRL
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	bvmf/N1BI34
Website	https://www.neurocrine.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	150.61x
Average P/E ratio (3Y)	36.3x
Average P/E ratio (5Y)	94.43x
Earnings yield	4.7%
EV/Earnings	21.85x
EV/EBIT	17.16x
EV/EBITDA	15.29x
EV/FCF	17.71x
EV/Sales	4.41x
FCF / EV yield	5.65%
FCF yield	5.67%
Forward P/E	12.15x
Graham number	19.4849
Graham upside	-50.09%
Lynch fair value	BRL 25.33
Lynch upside	-35.13%
P/(FCF - SBC) ratio	24.13x
P/(OCF - SBC) ratio	23.12x
P/B ratio	4.15x
P/E ratio	21.3x
P/FCF ratio	17.63x
P/OCF ratio	17.08x
P/S ratio	4.55x
Price / tangible book value	15.87x
Price/EBITDA ratio	16.8x
Sector forward P/E	11.05x
Sector P/E	41.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	25.67%
EBITDA margin	27.07%
Effective tax rate	24.96%
FCF margin	24.87%
Gross margin	64.48%
Operating margin	25.67%
Pretax margin	27.87%
Profit margin	20.91%
Profit per employee	BRL 1.5M
Profitable quarters	13
Profitable years	8
Revenue per employee	BRL 7M
ROA	11.7%
ROA (5Y)	8.57%
ROCE	19.31%
ROE	22.09%
ROE (5Y)	12.08%
ROIC	20.56%
ROIC (5Y)	20.75%
SBC / revenue	6.95%
Tax / revenue	6.96%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	101.21%
EPS growth (Q)	31.13%
EPS growth (QoQ)	-27.23%
EPS growth 3Y	57.74%
EPS growth 5Y	12.92%
EPS growth quarters	5
EPS growth years	4
FCF growth	64.63%
FCF growth (Q)	43.69%
FCF growth (QoQ)	-5.93%
FCF growth 3Y	45.81%
FCF growth 5Y	28.25%
Gross profit growth	37.17%
Gross profit growth (Q)	41.44%
Gross profit growth 3Y	24.47%
Gross profit growth 5Y	24.19%
Net income growth	102.56%
Net income growth (Q)	34.33%
Net income growth (QoQ)	-27.03%
Net income growth 3Y	58.73%
Net income growth 5Y	14.11%
Net income growth quarters	5
Net income growth years	4
OCF growth	58.31%
OCF growth (Q)	33.73%
OCF growth (QoQ)	-6.45%
OCF growth 3Y	44.74%
OCF growth 5Y	27.69%
Operating income growth	73.51%
Operating income growth (Q)	46.15%
Operating income growth 3Y	43.27%
Operating income growth 5Y	28.7%
Revenue growth	34.42%
Revenue growth (Q)	39.49%
Revenue growth (QoQ)	17.74%
Revenue growth 10Y	71.87%
Revenue growth 3Y	26.34%
Revenue growth 5Y	26.74%
Revenue growth quarters	20
Revenue growth years	9

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	BRL -143.5M
Depreciation and amortization	BRL 254.2M
EBIT	BRL 4.5B
EBITDA	BRL 4.7B
EPS	BRL 1.83
Financing cash flow	BRL 311.9M
Free cash flow	BRL 4.5B
Free cash flow minus SBC	BRL 3.3B
Gross profit	BRL 11.3B
Income taxes	BRL 1.2B
Investing cash flow	BRL -4.6B
Net cash flow	BRL 346.6M
Net income	BRL 3.7B
Operating cash flow minus SBC	BRL 3.4B
Operating income	BRL 4.5B
Revenue	BRL 17.5B
Stock-based compensation	BRL 1.2B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	6.57
Book value per share	BRL 188.34
Debt / EBITDA	0.47
Debt / equity	0.12
Debt / FCF	0.53
Goodwill	BRL 2.7B
Interest coverage	298.62
Long-term assets	BRL 19B
Long-term liabilities	BRL 3.9B
Net cash (debt)	BRL -372M
Net cash / market cap	-0.47%
Net debt / EBITDA	0.08
Net debt / equity	0.02
Net debt / FCF	0.08
Piotroski F-Score	6
Property, plant and equipment	BRL 2.9B
Shareholders' equity	BRL 19.1B
Tangible book value	BRL 5B
Tangible book value per share	BRL 49.31
Total assets	BRL 27.8B
Total cash	BRL 2B
Total debt	BRL 2.4B
Total liabilities	BRL 8.6B
WACC	6.28%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.73
Current assets	BRL 8.8B
Current liabilities	BRL 4.7B
Current ratio	1.87
Inventory turnover	14.88
Net working capital	BRL 2.2B
Quick ratio	1.46
Working capital	BRL 4B
Working capital turnover	17.79

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.78%
Shareholder yield	-0.78%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	BRL 37.63
1D price change	-0.41%
1M price change	8.44%
1M total return	8.44%
1W price change	9.17%
1W total return	9.17%
1Y price change	1.46%
1Y return CAGR	1.46%
1Y total return	1.46%
20-day SMA	BRL 36.55
200-day SMA	BRL 36.81
3M price change	-12.23%
3M total return	-12.23%
3Y price change	45.73%
3Y return CAGR	13.37%
3Y total return	45.73%
50-day SMA	BRL 39.42
50-day SMA vs 200-day SMA	50over200
52-week high	BRL 45.78
52-week high date	2026-07-07
52-week low	BRL 31.51
52-week low date	2026-02-24
5Y price change	52.2%
5Y return CAGR	8.77%
5Y total return	52.2%
6M price change	23.47%
6M total return	23.47%
All-time high	BRL 45.78
All-time high date	2026-07-07
All-time low	BRL 19.58
All-time low date	2022-05-09
Average true range (ATR)	BRL 0.92
Average volume	2.5K
Beta (5Y)	0.4
Change from 52-week high	-14.72%
Change from 52-week low	23.9%
Change from all-time high	-14.72%
Change from all-time low	99.39%
Change from open	0.1%
Day's gap	-0.51%
Dollar volume	BRL 2,538
High price	BRL 39.28
Low price	BRL 38.56
Monthly RSI	53.2
Open price	BRL 39.00
Position in 52-week range	66.67%
Previous close	BRL 39.20
Price vs 150-day SMA	3.75%
Price vs 20-day SMA	6.82%
Price vs 200-day SMA	6.05%
Price vs 50-day SMA	-0.95%
Relative volume	0.03
RSI	59.92
Sharpe ratio	0.47
Sharpe ratio (3Y)	0.49
Sortino ratio	0.78
Sortino ratio (3Y)	0.81
Volume	65
Weekly RSI	52
YTD price change	-3.17%
YTD total return	-3.17%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	100.4M
Shares change (QoQ)	0.77%
Shares change (YoY)	0.78%
Shares held by insiders	1.2%
Shares held by institutions	102.46%
Short ratio	4.9 days

Deeper analysis on BVMF/N1BI34

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BVMF/N1BI34 report

Is a complete BVMF/N1BI34 research report available?

No complete published report is available for bvmf/N1BI34 (BVMF/N1BI34) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BVMF/N1BI34 (BVMF/N1BI34)

Price

Financial snapshot

Fair-value bridge

Latest news · BVMF/N1BI34

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BVMF/N1BI34 indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BVMF/N1BI34

Frequently asked questions